BioSpace News Archive

KALA BIO, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635.

Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024.

Iovance Biotherapeutics, Inc. announced that on January 18, 2024, the Company approved the grant of inducement stock options covering an aggregate of 51,375 shares of Iovance’s common stock to six new non-executive employees.

Alpha Cognition Inc. announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company.

Mirum Pharmaceuticals, Inc. announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum’s Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units under Mirum’s 2020 Inducement Plan.

InkSpace Imaging announced the appointment of Dr. E. Brian Welch, PhD, MBA, as Vice President of Clinical Partnerships.

Myomo, Inc. announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing institutional investors as well as certain insiders of the Company, for the purchase and sale of 1,578,948 shares of common stock at a purchase price of $3.80 per share.

Jacobio Pharmaceuticals announced data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.